Cargando…

Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Neoadjuvant chemotherapy may improve overall survival (OS) in ‘borderline’ resectable pancreatic cancer (RPC). Whether the results are the same in upfront RPC is unknown. MATERIALS AND METHODS: To evaluate the association of neoadjuvant treatment and survival outcomes in RPC, a systemati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uson Junior, P.L.S., Dias e Silva, D., de Castro, N.M., da Silva Victor, E., Rother, E.T., Araújo, S.E.A., Borad, M.J., Moura, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024142/ https://www.ncbi.nlm.nih.gov/pubmed/36638709 http://dx.doi.org/10.1016/j.esmoop.2022.100771

Ejemplares similares

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2022)

Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival
por: Botrus, Gehan, et al.
Publicado: (2022)

Neoadjuvant therapy for resectable pancreatic cancer
por: Rahman, Sheikh Hasibur, et al.
Publicado: (2017)

Neoadjuvant therapy for resectable pancreatic cancers
por: Inoue, Yosuke, et al.
Publicado: (2022)

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2023)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
por: Lambert, Aurélien, et al.
Publicado: (2021)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
por: Mikulic, Danko, et al.
Publicado: (2021)

Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research
por: Cloyd, Jordan M, et al.
Publicado: (2020)

Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications
por: Deig, Christopher Ryan, et al.
Publicado: (2022)

Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
por: Kim, Dong Uk
Publicado: (2022)

Arterial Divestment and Resection in Post-neoadjuvant Pancreatic Adenocarcinoma
por: Limbu, Yugal, et al.
Publicado: (2021)

Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?
por: Vivarelli, Marco, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons
por: Nichols, Romaine Charles, et al.
Publicado: (2019)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Nomogram Predicting Overall Survival of Resected Locally Advanced Rectal Cancer Patients with Neoadjuvant Chemoradiotherapy
por: Song, Jianyuan, et al.
Publicado: (2020)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?
por: Motoi, Fuyuhiko, et al.
Publicado: (2020)

Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift
por: Chawla, Akhil, et al.
Publicado: (2019)

Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer
por: Okabayashi, Takehiro, et al.
Publicado: (2022)

Corrigendum to: Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?
por: Kim, Dong Uk
Publicado: (2023)

Role for Neoadjuvant Systemic Therapy for Potentially Resectable Pancreatic Cancer
por: Smaglo, Brandon G.
Publicado: (2023)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
por: Rajagopalan, Malolan S, et al.
Publicado: (2013)

Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival in Pancreatoduodenectomy for Pancreatic Cancer
por: Augustinus, Simone, et al.
Publicado: (2023)

Recent advances in understanding cholangiocarcinoma
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2020)

Does resection improve overall survival for intrahepatic cholangiocarcinoma with nodal metastases?
por: Sweigert, Patrick J., et al.
Publicado: (2020)

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
por: Byrne, Katelyn T., et al.
Publicado: (2021)

Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
por: Kim, Hyeong Seok, et al.
Publicado: (2017)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021)

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
por: Katz, Matthew H G, et al.
Publicado: (2023)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

A 25-gene classifier predicts overall survival in resectable pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2017)

Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report
por: Dias e Silva, Douglas, et al.
Publicado: (2023)

Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Cloyd, Jordan M., et al.
Publicado: (2020)

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
por: Katz, Matthew H. G., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_81kq5ob2tpquqr29b9ufhtqo38